1![FOR IMMEDIATE RELEASE The Gores Group Completes Sale of Therakos Leading Immunotherapy Company Achieved Significant Growth Following Carve-out from Former Division of Johnson & Johnson LOS ANGELES, CA, September 28, 2015 FOR IMMEDIATE RELEASE The Gores Group Completes Sale of Therakos Leading Immunotherapy Company Achieved Significant Growth Following Carve-out from Former Division of Johnson & Johnson LOS ANGELES, CA, September 28, 2015](https://www.pdfsearch.io/img/a7ba79da63ebb1686de1871e8327b225.jpg) | Add to Reading ListSource URL: www.gores.comLanguage: English - Date: 2015-09-28 03:05:27
|
---|
2![Award ID: CP130023 Project Title: Novel Ceramide-modulating Therapeutics for Cancer Use Award Mechanism: Company Formation Award ID: CP130023 Project Title: Novel Ceramide-modulating Therapeutics for Cancer Use Award Mechanism: Company Formation](https://www.pdfsearch.io/img/a1935acb980f06dd5a996ca2ff67aca7.jpg) | Add to Reading ListSource URL: www.cprit.state.tx.usLanguage: English - Date: 2015-03-24 12:30:06
|
---|
3![Legend Non-Hodgkin Lymphoma (NHL) Open to AccrualPh 2b Open-label, Randomized Two Arm Study of Selinexor plus Low Legend Non-Hodgkin Lymphoma (NHL) Open to AccrualPh 2b Open-label, Randomized Two Arm Study of Selinexor plus Low](https://www.pdfsearch.io/img/c6905bc51bdf15246ce1453e7809b8fc.jpg) | Add to Reading ListSource URL: cancer.ucsf.eduLanguage: English - Date: 2014-10-06 14:59:55
|
---|
4![Mesothelioma Articles - Merck & Co: Zolinza becomes first app... Mesothelioma Articles - Merck & Co: Zolinza becomes first app...](https://www.pdfsearch.io/img/a6a8f64697a52c95a4ffadd339b2c29e.jpg) | Add to Reading ListSource URL: www.mirg.orgLanguage: English - Date: 2010-10-19 13:01:20
|
---|
5![Summary of ARC Future Fellowships Proposals for Funding to Commence inVictoria Ludwig Institute for Cancer Research Limited FT0992234 Summary of ARC Future Fellowships Proposals for Funding to Commence inVictoria Ludwig Institute for Cancer Research Limited FT0992234](https://www.pdfsearch.io/img/885e5f127b693d8964de3ca7644d954c.jpg) | Add to Reading ListSource URL: arc.gov.auLanguage: English - Date: 2009-09-01 22:06:35
|
---|
6![Journal of IMAB - Annual Proceeding (Scientific Papers) 2010, vol. 16, book 3 MODERN CLASSIFICATION OF CUTANEOUS PSEUDOLYMPHOMAS S. Shtilionova1, P.Drumeva1, M. Balabanova2, I. Krasnaliev3 1) Department of dermatology a Journal of IMAB - Annual Proceeding (Scientific Papers) 2010, vol. 16, book 3 MODERN CLASSIFICATION OF CUTANEOUS PSEUDOLYMPHOMAS S. Shtilionova1, P.Drumeva1, M. Balabanova2, I. Krasnaliev3 1) Department of dermatology a](https://www.pdfsearch.io/img/128c187186828ccf98550e7da1223127.jpg) | Add to Reading ListSource URL: www.journal-imab-bg.orgLanguage: English - Date: 2011-04-19 08:29:57
|
---|
7![Subject index A ABCD 56, 58 ABCDE criteria 85 Abrikossoff tumour 274 Subject index A ABCD 56, 58 ABCDE criteria 85 Abrikossoff tumour 274](https://www.pdfsearch.io/img/f0e75b6f4c900b19cc3a80f75cdcc3fb.jpg) | Add to Reading ListSource URL: www.iarc.frLanguage: English - Date: 2015-02-25 08:39:40
|
---|
8![Contents 1 Keratinocytic tumours WHO and TNM classification Introduction Basal cell carcinoma Superficial basal cell carcinoma Contents 1 Keratinocytic tumours WHO and TNM classification Introduction Basal cell carcinoma Superficial basal cell carcinoma](https://www.pdfsearch.io/img/a8b2cf37d262dab5742a477f0e984aec.jpg) | Add to Reading ListSource URL: www.iarc.frLanguage: English - Date: 2015-02-25 08:39:40
|
---|
9![References 1. AnonNational Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 2729, 1992. Am J Dermatopathol 15: 34-43. References 1. AnonNational Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 2729, 1992. Am J Dermatopathol 15: 34-43.](https://www.pdfsearch.io/img/8eb7ec621a0f6a136ad8c071aff391fe.jpg) | Add to Reading ListSource URL: www.iarc.frLanguage: English - Date: 2015-02-25 08:39:40
|
---|
10![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ISTODAX safely and effectively. See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ISTODAX safely and effectively. See full prescribing information for](https://www.pdfsearch.io/img/a23a7394ca649fafd626a6f9ca3b69f3.jpg) | Add to Reading ListSource URL: assets1.celgene.comLanguage: English - Date: 2014-10-16 15:59:35
|
---|